Clearside BioMedical specializes in the suprachoroidal administration of therapeutic products to treat retinal diseases, utilizing a proprietary method that allows drugs to be precisely delivered to the back of the eye. Their FDA-approved product, XIPERE®, targets macular edema associated with uveitis, addressing the need for effective treatments in this area.
Funding
$15M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many retinal diseases are treated with drugs that cannot effectively reach the back of the eye due to physiological barriers. Traditional methods of drug delivery may not provide sufficient drug concentrations at the site of disease, limiting therapeutic efficacy.
Solution
Clearside BioMedical focuses on treating retinal diseases through suprachoroidal administration, a targeted drug delivery method to the back of the eye. Their proprietary technology allows precise placement of therapeutic agents between the choroid and sclera, enabling spherical dispersion towards posterior regions. This approach facilitates absorption into adjacent, diseased tissue, potentially improving treatment outcomes for serious ocular conditions. Clearside's lead product, XIPERE®, is the first FDA-approved therapeutic delivered via this route.
Target Audience
The primary target audience includes patients with retinal diseases, particularly those with macular edema associated with uveitis, and the ophthalmologists and retinal specialists who treat them.
Features
- Suprachoroidal Space (SCS®) injection platform for targeted drug delivery
- Precise administration to the back of the eye, the location of many irreversible and debilitating ocular conditions
- XIPERE® (triamcinolone acetonide injectable suspension) is the first and only FDA-approved product for suprachoroidal administration
- XIPERE® is indicated for macular edema associated with uveitis
- Clinical programs focused on developing treatments to preserve and improve vision